γ-secretase inhibitors for Alzheimer's disease: Balancing efficacy and toxicity

Drugs in R and D

Volumn 7, Issue 2, 2006, Pages 87-97

  Barten, Donna M ^a   Meredith Jr , Jere E ^a   Zaczek, Robert ^a   Houston, John G ^a   Albright, Charles F ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPSIN; AMYLOID BETA PROTEIN; BETA SECRETASE INHIBITOR; BIOLOGICAL MARKER; BMS 299897; FLURBIPROFEN; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; IBUPROFEN; LY 411575; LY 450139; MEMBRANE RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; NOTCH RECEPTOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CELL FATE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TOXICITY; HUMAN; HYPOTHESIS; NONHUMAN; OCCULT BLOOD; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DEGRADATION; PROTEIN FUNCTION; REVIEW; SPLEEN DISEASE; THYMUS DISEASE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ENDOPEPTIDASES; COGNITION; ENDOPEPTIDASES; HUMANS; MODELS, BIOLOGICAL; PROTEASE INHIBITORS; RECEPTORS, NOTCH; TREATMENT OUTCOME;

EID: 33645234720     PISSN: 11745886     EISSN: 11745886     Source Type: Journal    
DOI: 10.2165/00126839-200607020-00003     Document Type: Review

References (92)

1. Grundman M, Petersen RC, Ferris SH, et al. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol 2004; 61 (1): 59-66
2. Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004; 44 (1): 181-93
3. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging 1997; 18 (4 Suppl.): S1-2
4. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001; 81 (2): 741-66
5. Wolfe MS, Kopan R. Intramembrane proteolysis: theme and variations. Science 2004; 305 (5687): 1119-23
6. Herreman A, Hartmann D, Annaert W, et al. Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency. Proc Natl Acad Sci U S A 1999; 96 (21): 11872-7
7. Lai MT, Chen E, Crouthamel MC, et al. Presenilin-1 and presenilin-2 exhibit distinct yet overlapping gamma-secretase activities. J Biol Chem 2003; 278 (25): 22475-81
8. Kobayashi DT, Chen KS. Behavioral phenotypes of amyloid-based genetically modified mouse models of Alzheimer's disease. Genes Brain Behav 2005; 4 (3): 173-96
9. Caughey B, Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 2003; 26: 267-98
10. Cleary JP, Walsh DM, Hofmeister JJ, et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 2005; 8 (1): 79-84
11. Wilson CA, Doms RW, Lee VM. Distinct presenilin-dependent and presenilin-independent gamma-secretases are responsible for total cellular Abeta production. J Neurosci Res 2003; 74 (3): 361-9
12. Pollack SJ, Lewis H. Secretase inhibitors for Alzheimer's disease: challenges of a promiscuous protease. Curr Opin Investig Drugs 2005; 6 (1): 35-47
13. Donoviel DB, Hadjantonakis A-K, Ikeda M, et al. Mice lacking both presenilin genes exhibit early embryonic patterning defects. Genes Dev 1999; 13 (21): 2801-10
14. Li T, Ma G, Cai H, et al. Nicastrin is required for assembly of presenilin/gamma-secretase complexes to mediate Notch signaling and for processing and trafficking of beta-amyloid precursor protein in mammals. J Neurosci 2003; 23 (8): 3272-7
15. Serneels L, Dejaegere T, Craessaerts K, et al. Differential contribution of the three Aph1 genes to gamma-secretase activity in vivo. Proc Natl Acad Sci U S A 2005; 102 (5): 1719-24
16. Hamada Y, Kadokawa Y, Okabe M, et al. Mutation in ankyrin repeats of the mouse Notch2 gene induces early embryonic lethality. Development 1999; 126 (15): 3415-24
17. Swiatek PJ, Lindsell CE, del Amo FF, et al. Notch1 is essential for postimplantation development in mice. Genes Dev 1994; 8 (6): 707-19
18. Conlon RA, Reaume AG, Rossant J. Notch1 is required for the coordinate segmentation of somites. Development 1995; 121 (5): 1533-45
19. Huppert SS, Le A, Schroeter EH, et al. Embryonic lethality in mice homozygous for a processing-deficient allele of Notch1. Nature 2000; 405: 966-70
20. Li J, Fici GJ, Mao CA, et al. Positive and negative regulation of the gamma-secretase activity by nicastrin in a murine model. J Biol Chem 2003; 278 (35): 33445-9
21. Ma G, Li T, Price DL, et al. APH-1a is the principal mammalian APH-1 isoform present in gamma-secretase complexes during embryonic development. J Neurosci 2005; 25 (1): 192-8
22. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science 1999; 284 (5415): 770-6
23. Kadesch T. Notch signaling: a dance of proteins changing partners. Exp Cell Res 2000; 260 (1): 1-8
24. Brou C, Logeat F, Gupta N, et al. A novel proteolytic cleavage involved in notch signaling: the role of the disintegrin-metalloprotease TACE. Mol Cell 2000; 5 (2): 207-16
25. Mumm JS, Schroeter EH, Saxena MT, et al. A ligand-induced extracellular cleavage regulates gamma-secretase-like proteolytic activation of notch1. Mol Cell 2000; 5 (2): 197-206
26. Pan D, Rubin GM. Kuzbanian controls proteolytic processing of Notch and mediates lateral inhibition during Drosophila and vertebrate neurogenesis. Cell 1997; 90 (2): 271-80
27. Schroeter EH, Kisslinger JA, Kopan R. Notch-1 signaling requires ligand-induced proteolytic release of intracellular domain. Nature 1998; 393 (6683): 382-6
28. Kopan R, Schroeter EH, Weintraub H, et al. Signal transduction by activated mNotch: importance of proteolytic processing and its regulation by the extracellular domain. Proc Natl Acad Sci U S A 1996; 93 (4): 1683-8
29. Jarriault S, Le Bail O, Hirsinger E, et al. Delta-1 activation of notch-1 signaling results in HES-1 transactivation. Mol Cell Biol 1998; 18 (12): 7423-31
30. Ohtsuka T, Ishibashi M, Gradwohl G, et al. Hes1 and Hes5 as notch effectors in mammalian neuronal differentiation. EMBO J 1999; 18 (8): 2196-207
31. Dovey HF, John V, Anderson JP, et al. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem 2001; 76 (1): 173-81
32. Lanz TA, Himes CS, Pallante G, et al. The gamma-secretase inhibitor N-[N- (3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester reduces A beta levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice. J Pharmacol Exp Ther 2003; 305 (3): 864-71
33. Lanz TA, Hosley JD, Adams WJ, et al. Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[ (2S)-2- (3,5-difluorophenyl)-2- hydroxyethanoyl]-N1-[ (7S)-5-methyl-6-oxo -6,7-dihydro-5H-dibenzo[b,d]azepin-7- yl]-L-alaninamide (LY-411575). J Pharmacol Exp Ther 2004; 309 (1): 49-55
34. Wong GT, Manfra D, Poulet FM, et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 2004; 279 (13): 12876-82
35. Milano J, McKay J, Dagenais C, et al. Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol Sci 2004; 82 (1): 341-58
36. Barten DM, Guss VL, Corsa JA, et al. Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor. J Pharmacol Exp Ther 2005; 312 (2): 635-43
37. Anderson JJ, Holtz G, Baskin PP, et al. Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897. Biochem Pharmacol 2005; 69 (4): 689-98
38. Best JD, Jay MT, Otu F, et al. Quantitative measurement of changes in amyloid-{beta} (40) in the rat brain and cerebrospinal fluid following treatment with the {gamma}-secretase inhibitor LY-411575 [N2-[ (2S)-2- (3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[ (7S)-5-methyl-6-oxo-6,7-dihydro-5H- dibenzo[b,d]azepin-7-yl]-L-alaninamide]. J Pharmacol Exp Ther 2005; 313 (2): 902-8
39. Janus C, Pearson J, McLaurin J, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000; 408 (6815): 979-82
40. Wilcock DM, Rojiani A, Rosenthal A, et al. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 2004; 1 (1): 24-35
41. Morgan D, Diamond DM, Gottschall PE, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000; 408 (6815): 982-5
42. Dodart JC, Bales KR, Gannon KS, et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 2002; 5 (5): 452-7
43. Kotilinek LA, Bacskai B, Westerman M, et al. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci 2002; 22 (15): 6331-5
44. Billings LM, Oddo S, Green KN, et al. Intraneuronal abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 2005; 45 (5): 675-88
45. Ohno M, Sametsky EA, Younkin LH, et al. BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. Neuron 2004; 41 (1): 27-33
46. Comery TA, Martone RL, Aschmies S, et al. Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 2005; 25 (39): 8898-902
47. Feng R, Rampon C, Tang YP, et al. Deficient neurogenesis in forebrain-specific presenilin-1 knockout mice is associated with reduced clearance of hippocampal memory traces. Neuron 2001; 32 (5): 911-26
48. Yu H, Saura CA, Choi SY, et al. APP processing and synaptic plasticity in presenilin-1 conditional knockout mice. Neuron 2001; 31 (5): 713-26
49. Dewachter I, Reverse D, Caluwaerts N, et al. Neuronal deficiency of presenilin 1 inhibits amyloid plaque formation and corrects hippocampal long-term potentiation but not a cognitive defect of amyloid precursor protein [V717I] transgenic mice. J Neurosci 2002; 22 (9): 3445-53
50. Costa RM, Honjo T, Silva AJ. Learning and memory deficits in Notch mutant mice. Curr Biol 2003; 13 (15): 1348-54
51. Costa RM, Drew C, Silva AJ. Notch to remember. Trends Neurosci 2005; 28 (8): 429-35
52. Saura CA, Chen G, Malkani S, et al. Conditional inactivation of presenilin 1 prevents amyloid accumulation and temporarily rescues contextual and spatial working memory impairments in amyloid precursor protein transgenic mice. J Neurosci 2005; 25 (29): 6755-64
53. Chang KA, Suh YH. Pathophysiological roles of amyloidogenic carboxy-terminal fragments of the beta-amyloid precursor protein in Alzheimer's disease. J Pharmacol Sci 2005; 97 (4): 461-71
54. Rockenstein E, Mante M, Alford M, et al. High beta-secretase activity elicits neurodegeneration in transgenic mice despite reductions in amyloid-beta levels: implications for the treatment of Alzheimer disease. J Biol Chem 2005; 280 (38): 32957-67
55. Rutten BP, Wirths O, Van de Berg WD, et al. No alterations of hippocampal neuronal number and synaptic bouton number in a transgenic mouse model expressing the beta-cleaved C-terminal APP fragment. Neurobiol Dis 2003; 12 (2): 110-20
56. Kamenetz F, Tomita T, Hsieh H, et al. APP processing and synaptic function. Neuron 2003; 37 (6): 925-37
57. Gridley T. Notch signaling and inherited disease syndromes. Hum Mol Genet 2003; 12 Spec No 1: R9-13
58. McCright B. Notch signaling in kidney development. Curr Opin Nephrol Hypertens 2003; 12 (1): 5-10
59. Yoon K, Gaiano N. Notch signaling in the mammalian central nervous system: insights from mouse mutants. Nat Neurosci 2005; 8 (6): 709-15
60. Searfoss GH, Jordan WH, Calligaro DO, et al. Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional gamma-secretase inhibitor. J Biol Chem 2003; 278 (46): 46107-16
61. Radtke F, Clevers H. Self-renewal and cancer of the gut: two sides of a coin. Science 2005; 307 (5717): 1904-9
62. Schonhoff SE, Giel-Moloney M, Leiter AB. Minireview: development and differentiation of gut endocrine cells. Endocrinology 2004; 145 (6): 2639-44
63. Jensen J, Pedersen EE, Galante P, et al. Control of endodermal endocrine development by Hes-1. Nat Genet 2000; 24 (1): 36-44
64. van Es JH, van Gijn ME, Riccio O, et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 2005; 435 (7044): 959-63
65. Fre S, Huyghe M, Mourikis P, et al. Notch signals control the fate of immature progenitor cells in the intestine. Nature 2005; 435 (7044): 964-8
66. Doerfler P, Shearman MS, Perlmutter RM. Presenilin-dependent gamma-secretase activity modulates thymocyte development. Proc Natl Acad Sci U S A 2001; 98 (16): 9312-7
67. Radtke F, Wilson A, Mancini SJ, et al. Notch regulation of lymphocyte development and function. Nat Immunol 2004; 5 (3): 247-53
68. Maillard I, Fang T, Pear WS. Regulation of lymphoid development, differentiation, and function by the notch pathway. Annu Rev Immunol 2005; 23: 945-74
69. Han H, Tanigaki K, Yamamoto N, et al. Inducible gene knock-out of transcription factor recombination signal binding protein-J reveals its essential role in T versus B lineage decision. Int Immunol 2002; 14 (6): 637-45
70. Radtke F, Wilson A, Stark G, et al. Deficient T cell fate specification in mice with an induced inactivation of Notch1. Immunity 1999; 10 (5): 547-58
71. Tanigaki K, Tsuji M, Yamamoto N, et al. Regulation of alphabeta/gammadelta T cell lineage commitment and peripheral T cell responses by Notch/RBP-J signaling. Immunity 2004; 20 (5): 611-22
72. Murphy KM, Reiner SL. The lineage decisions of helper T cells. Nat Rev Immunol 2002; 2 (12): 933-44
73. Saito T, Chiba S, Ichikawa M, et al. Notch2 is preferentially expressed in mature B cells and indispensable for marginal zone B lineage development. Immunity 2003; 18 (5): 675-85
74. Tanigaki K, Han H, Yamamoto N, et al. Notch-RBP-J signaling is involved in cell fate determination of marginal zone B cells. Nat Immunol 2002; 3 (5): 443-50
75. Min H, Montecino-Rodriguez E, Dorshkind K. Effects of aging on early B- and T-cell development. Immunol Rev 2005; 205: 7-17
76. Fulop T, Larbi A, Wikby A, et al. Dysregulation of T-cell function in the elderly: scientific basis and clinical implications. Drugs Aging 2005; 22 (7): 589-603
77. Saura CA, Choi SY, Beglopoulos V, et al. Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron 2004; 42 (1): 23-36
78. Beglopoulos V, Sun X, Saura CA, et al. Reduced beta-amyloid production and increased inflammatory responses in presenilin conditional knock-out mice. J Biol Chem 2004; 279 (45): 46907-14
79. Lewis HD, Perez Revuelta BI, Nadin A, et al. Catalytic site-directed gamma-secretase complex inhibitors do not discriminate pharmacologically between Notch S3 and beta-APP cleavages. Biochemistry 2003; 42 (24): 7580-6
80. Weller RO. How well does the CSF inform upon pathology in the brain in Creutzfeldt-Jakob and Alzheimer's diseases? J Pathol 2001; 194 (1): 1-3
81. Chodobski A, Szmydynger-Chodobska J. Choroid plexus: target for polypeptides and site of their synthesis. Microsc Res Tech 2001; 52 (1): 65-82
82. Johanson C, McMillan P, Tavares R, et al. Homeostatic capabilities of the choroid plexus epithelium in Alzheimer's disease. Cerebrospinal Fluid Res 2004; 1 (1): 3-19
83. Weller RO. Pathology of cerebrospinal fluid and interstitial fluid of the CNS: significance for Alzheimer disease, prion disorders and multiple sclerosis. J Neuropathol Exp Neurol 1998; 57 (10): 885-94
84. Siemers E, Skinner M, Dean RA, et al. Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. Clin Neuropharmacol 2005; 28 (3): 126-32
85. Kukar T, Murphy MP, Eriksen JL, et al. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nat Med 2005; 11 (5): 545-50
86. Weggen S, Eriksen JL, Das P, et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001; 414 (6860): 212-6
87. Eriksen JL, Sagi SA, Smith TE, et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest 2003; 112 (3): 440-9
88. Takahashi Y, Hayashi I, Tominari Y, et al. Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces Abeta 42 generation. J Biol Chem 2003; 278 (20): 18664-70
89. Weggen S, Eriksen JL, Sagi SA, et al. Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. J Biol Chem 2003; 278 (34): 31831-7
90. Beher D, Clarke EE, Wrigley JD, et al. Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site: evidence for an allosteric mechanism. J Biol Chem 2004; 279 (42): 43419-26
91. Lleo A, Berezovska O, Herl L, et al. Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation. Nat Med 2004; 10 (10): 1065-6
92. Zhou Y, Su Y, Li B, et al. Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho. Science 2003; 302 (5648): 1215-7